Suzanne L. Topalian

Suzanne L. Topalian, MD, is Director of the Melanoma Program at the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Professor of Surgery and Oncology at Johns Hopkins University School of Medicine. She holds the Bloomberg Distinguished Professorship in Cancer Immunotherapy. Dr. Topalian led the first clinical trial of anti-PD-1 therapy in cancer patients. Her landmark 2012 NEJM publication (PMID 22658127, 10,000+ citations) reported the first-in-human Phase 1 trial of nivolumab, demonstrating objective responses in 18-28% of patients with melanoma, renal cell carcinoma, and non-small cell lung cancer—unprecedented results that revolutionized cancer treatment. This pivotal trial established anti-PD-1 as a major advance in cancer immunotherapy and laid the foundation for FDA approvals of nivolumab and pembrolizumab. Dr. Topalian's 2012 NEJM paper also pioneered PD-L1 as a predictive biomarker, showing that tumor PD-L1 expression was associated with higher response rates—a finding that transformed clinical practice and informed regulatory approvals. Her research on tumor-infiltrating lymphocytes at the National Cancer Institute in the 1980s-1990s established fundamental understanding of T cell-based immunotherapy. Elected to the National Academy of Medicine (2016) and the American Academy of Arts and Sciences, Dr. Topalian received the William B. Coley Award (2013), the AACR-CRI Lloyd J. Old Award in Cancer Immunology (2015), and multiple other prestigious honors. As a pioneer of anti-PD-1 therapy and PD-L1 biomarker development, she has fundamentally transformed the treatment of advanced cancer.

Suzanne L. Topalian医学博士现任约翰霍普金斯大学医学院Bloomberg-Kimmel癌症免疫治疗研究所黑色素瘤项目主任以及外科与肿瘤学教授。她持有Bloomberg癌症免疫治疗杰出教授职位。 Topalian博士领导了首个抗PD-1疗法在癌症患者中的临床试验。她2012年NEJM里程碑论文(PMID 22658127, 引用10,000+次)报道了nivolumab的首个人体Phase 1试验，显示在黑色素瘤、肾细胞癌和非小细胞肺癌患者中18-28%的客观缓解率——这一前所未有的结果革命性地改变了癌症治疗。这一关键试验确立了抗PD-1作为癌症免疫治疗的重大进展，并为nivolumab和pembrolizumab的FDA批准奠定了基础。 Topalian博士的2012年NEJM论文还开创了PD-L1作为预测性生物标志物，显示肿瘤PD-L1表达与更高的缓解率相关——这一发现改变了临床实践并影响了监管批准。她在1980-1990年代在美国国家癌症研究所进行的肿瘤浸润淋巴细胞研究确立了基于T细胞的免疫治疗的基础理解。 Topalian博士2016年当选美国国家医学院院士和美国艺术与科学院院士，获William B. Coley奖(2013)、AACR-CRI Lloyd J. Old癌症免疫学奖(2015)以及多项其他殊荣。作为抗PD-1疗法和PD-L1生物标志物开发的先驱，她从根本上改变了晚期癌症的治疗。